Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Hilde De Winter"'
Autor:
Anne Goubier, Neeltje Steeghs, Carlos Gomez-Roca, Philippe Cassier, Elena Fernandez, Eelke Gort, Hilde De Winter, Vaia Stavropoulou, Nina Stojcheva, Paul Baverel, Jennifer Krieg, Kyriaki Ioannou, Ana Maria Florescu, Lea Hoenig, Bruno Baud-Berthier, Michael P Sanderson, Vladimir Kirkin, Philippe Legenne
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/16a42102bbb14121abeac1be930d0852
Autor:
Flora Peyvandi, Spero Cataland, Marie Scully, Paul Coppo, Paul Knoebl, Johanna A. Kremer Hovinga, Ara Metjian, Javier de la Rubia, Katerina Pavenski, Jessica Minkue Mi Edou, Filip Callewaert, Hilde De Winter
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S46-S47 (2021)
Objective: An integrated analysis based on the Phase 2 TITAN (NCT01151423) and Phase 3 HERCULES (NCT02553317) studies with caplacizumab (CPLZ) in acquired thrombotic thrombocytopenic purpura (aTTP) was performed to assess treatment differences on eff
Externí odkaz:
https://doaj.org/article/50e75989ab3e4389a9bb0fcf5b02f584
Autor:
Hilde De Winter, Elena Fernandez, Vaia Stavropoulou, Nina Stojcheva, Paul Baverel, Carlos Gomez-Roca, Eelke Gort, Neeltje Steeghs, Kyriaki Ioannou, Ana Maria Florescu, Jennifer Krieg, Patrick Mossi, Vladimir Kirkin, Philippe Legenne, Philippe Cassier
Publikováno v:
Late-Breaking Abstracts.
Autor:
Paul Knoebl, Javier de la Rubia, Filip Callewaert, Hilde De Winter, Johanna A. Kremer Hovinga, Spero R. Cataland, Marie Scully, Katerina Pavenski, Jessica Minkue Mi Edou, Flora Peyvandi, Ara Metjian, Paul Coppo
Publikováno v:
Blood Adv
The efficacy and safety of caplacizumab in individuals with acquired thrombotic thrombocytopenic purpura (aTTP) have been established in the phase 2 TITAN and phase 3 HERCULES trials. Integrated analysis of data from both trials was conducted to incr
Autor:
Hilde De Winter, Jan Canvin, Maria Laura Sargentini-Maier, Philip De Decker, Filip Callewaert, Claudia Tersteeg
Publikováno v:
Expert Review of Clinical Pharmacology. 12:537-545
Introduction: Caplacizumab is a humanized anti-von Willebrand Factor (vWF) Nanobody® for the treatment of acquired Thrombotic Thrombocytopenic Purpura (aTTP). Caplacizumab targets the A1-domain of vWF, inhibiting the interaction between vWF and plat
Autor:
Javier de la Rubia, Filip Callewaert, Marie Scully, Paul Knoebl, Hilde De Winter, Spero R. Cataland, Johanna A. Kremer Hovinga, Ara Metjian, Jessica Minkue Mi Edou, Paul Coppo, Katerina Pavenski, Flora Peyvandi
Publikováno v:
Journal of Thrombosis and Haemostasis
Knoebl, Paul; Cataland, Spero; Peyvandi, Flora; Coppo, Paul; Scully, Marie; Kremer Hovinga, Johanna A.; Metjian, Ara; de la Rubia, Javier; Pavenski, Katerina; Minkue Mi Edou, Jessica; De Winter, Hilde; Callewaert, Filip (2020). Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. Journal of thrombosis and haemostasis, 18(2), pp. 479-484. Wiley-Blackwell 10.1111/jth.14679
Knoebl, Paul; Cataland, Spero; Peyvandi, Flora; Coppo, Paul; Scully, Marie; Kremer Hovinga, Johanna A.; Metjian, Ara; de la Rubia, Javier; Pavenski, Katerina; Minkue Mi Edou, Jessica; De Winter, Hilde; Callewaert, Filip (2020). Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. Journal of thrombosis and haemostasis, 18(2), pp. 479-484. Wiley-Blackwell 10.1111/jth.14679
BACKGROUND Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening autoimmune thrombotic microangiopathy. Caplacizumab, an anti-von Willebrand Factor Nanobody® , is effective for treating aTTP episodes and is well tolerated.
Autor:
Paul Knöbl, Javier de la Rubia, Johanna A. Kremer Hovinga, Spero R. Cataland, Ara Metjian, Flora Peyvandi, Paul Coppo, Marie Scully, Debjit Biswas, R.K. Zeldin, Filip Callewaert, Hercules Investigators, Hilde De Winter, Katerina Pavenski
BACKGROUND In acquired thrombotic thrombocytopenic purpura (TTP), an immune-mediated deficiency of the von Willebrand factor-cleaving protease ADAMTS13 allows unrestrained adhesion of von Willebrand factor multimers to platelets and microthrombosis,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a37198cd06aaddd794a11158bd78bdca
https://www.zora.uzh.ch/id/eprint/175165/
https://www.zora.uzh.ch/id/eprint/175165/
Autor:
Javier de la Rubia, Paul Coppo, Hilde De Winter, Katerina Pavenski, Johanna A. Kremer Hovinga, Paul Knoebl, Filip Callewaert, Ara Metjian, Rui de Passos Sousa, Marie Scully, Flora Peyvandi, Spero R. Cataland
Publikováno v:
Blood. 134:2365-2365
Background: Acquired thrombotic thrombocytopenic purpura (aTTP) is an acute, life-threatening thrombotic microangiopathy that requires urgent and specialized treatment. Prior to the introduction of caplacizumab, the treatment for aTTP was based on da
Autor:
Javier de la Rubia, Hilde De Winter, Flora Peyvandi, Ara Metjian, Katerina Pavenski, Filip Callewaert, Marie Scully, Paul Knoebl, Paul Coppo, Rui de Passos Sousa, Johanna A. Kremer Hovinga, Spero R. Cataland
Publikováno v:
Blood. 134:2366-2366
Background: Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening autoimmune thrombotic microangiopathy that involves abnormal processing of von-Willebrand factor (vWF) and results in multiple organ dysfunction. Although aTT
Autor:
Ara Metjian, Paul Coppo, Katerina Pavenski, Javier de la Rubia, Filip Callewaert, Paul Knoebl, Flora Peyvandi, Spero R. Cataland, Marie Scully, Johanna A. Kremer Hovinga, Hilde De Winter
Publikováno v:
Blood. 134:4908-4908
Background: Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare but life-threatening thrombotic microangiopathy, with an untreated mortality rate of >90%. Prompt treatment with therapeutic plasma exchange (TPE) and immunosuppression improve